There are several health focused wearable watches on the market today but Google’s parent company Alphabet has developed a wearable watch primarily for cardiovascular health. The line is by Verily which has received a 510(k) clearance from the US Food and Drug Administration (FDA) that its wearable health watch is a medical device.
With this approval, Verily’s health monitoring wearable watch is safe and effective and gives the company the license to sell it legally in the US.
Verily is Alphabet’s life sciences research organization. It has been working on this device for several years and specifically for use in clinical or research projects and purposes. The whole purpose of this device is to provide an inconspicuous wearable watch which would be a biosening monitor.
It has been use so far with thousands of patients in clinical research studies in the area of cardiovascular health which is the number one health killer for both men and women in the US.
According to Digital Trends, Verily’s wearable health monitoring device’s clearance by the FDA makes it “a Class II medical device for its on-demand ECG feature, with a prescription-only device intended to record, store, transfer and display single-channel ECG rhythms.” Its not meant for general public use but specifically for health professionals and patients with cardiovascular disease that are on a program that necessitates keeping track of their heart health conditions by monitoring their ECG rhythms.
Project Baseline is a current research being done by Verily using its device to collect data from a large group of people to eventually provide a source of measurement that would map out various heart conditions and hopefully to prevent heart diseases. Some of the data being collected by Verily’s heart health monitors are “biometric data like ECGs and genomic and proteomic data, as well as traditional clinical data like electronic health records and medical images,” as reported by Digital Trends.
“This work may ultimately give us insights into the utility of integrating mobile health data into the clinical care environment, and how these data can support the physician-patient relationship… Together, we are working towards a future where we can use devices, like the FDA-cleared Study Watch, to inform real-world, personalized care decisions and help us move to proactive healthcare,”says Michael V. McConnell, M.D., Head of Cardiovascular Health Innovations at Verily.